Alzheimer's Treatment

Desperate For a Cure: The Search for New Alzheimer's Treatments

"Desperate For A Cure: The Search For New Alzheimer's Treatments", a new five-part series by NPR's Sean Corcoran, aired this week on WCAI and will air again next week on WGBH in Boston.

Drs. Sam Gandy and Scott Noggle Receive NIH Grant

Drs. Sam Gandy and Scott Noggle have received an NIH grant to gain new insights and identify potential therapies for Alzheimer’s disease.

Cholesterol and Alzheimer's: A Big Step Forward

For several years now, researchers have been aware of important links between cholesterol and Alzheimer's disease. A new study by Dr. Dora Kovacs and her team at Massachusetts General Hospital brings us one step closer to a potential drug that could interrupt the disease process.

Targretin Fails: High Hopes Dashed for a New Treatment for Alzheimer’s

While many were anxious to accept initial findings showing a drug known as Targretin’s “too good to be true” lab results with Alzheimer’s disease, subsequent attempts to confirm and replicate the original data regarding the ability of Targretin to remove amyloid plaques, the cardinal lesion of the disease, have largely failed. Cure Alzheimer’s Fund Research Consortium members Dr. Sangram Sisodia, professor of neuroscience at the University of Chicago and Dr.

New Alzheimer’s Gene, CD33, May Hold Key to Treatment

BOSTON— Excessive levels of the protein CD33 can impede the clearance of the plaque-forming protein, amyloid beta, the key component of senile plaques in the brains of Alzheimer’s disease patients. The discovery, made by Dr. Rudolph Tanzi and colleagues at Massachusetts General Hospital, and co-funded by the Cure Alzheimer’s Fund and the National Institute of Mental Health (NIMH) will be published in the journal Neuron.

Eli Lilly Drug Slows Decline in Early-Stage Patients

October 9 -- Eli Lilly announced encouraging results yesterday involving their experimental drug Solanezumab. Solanezumab is an antibody aimed at lowering beta-amyloid levels in the brain. In trials lasting 18 months, patients with mild Alzheimer's symptoms taking Solanezumab showed significantly less cognitive decline -- 34% less -- compared with patients taking the placebo.

Coconut Oil: A Scientific Perspective

Cure Alzheimer’s Fund has received many questions about the value of coconut oil in combatting Alzheimer’s. We’ve asked Rudy Tanzi, Ph.D., to respond to these inquiries generically, knowing that a) there is currently no peer-reviewed clinical research available regarding efficacy of coconut oil in treating or preventing Alzheimer’s, and b) every personal situation and experience is unique. Rudy has agreed to provide his perspective on this, given those two giant caveats.

Bexarotene, a new wonder drug for Alzheimer’s?

Dr. Gary Landreth and colleagues at Case Western Reserve published a paper online in Science Express yesterday that received much attention because of the rather stunning results it reports in stopping and even reversing “a broad range of Abeta-induced deficits."

Steve Wagner Receives NIH ‘Blueprint’ Grant

The CAF approach is working.

UC San Diego neuroscientist Steve Wagner, a previous recipient of two substantial grants from Cure Alzheimer’s Fund (CAF), has been awarded a $1 million NIH “Blueprint” grant for the fast-track development of a promising Alzheimer’s drug therapy.

“This is further validation of our venture model,” says CAF President and CEO Tim Armour. “We’ve always been willing to take considerable risk for the prospect of faster progress. Steve’s project is a sterling example of why our founders adopted this strategy. Thanks in part to CAF’s support for Wagner’s research, the world is now much closer to a promising new class of Alzheimer’s drugs.”